Table 4 Monthly MOUD Utilization Trends

New Counts of MOUD

Intervention Phase (12 Ms)

Sustainability Phase (12 Ms)

Annual Est. Change

t-value

P-Value

n sites

Annual Est. Change

T-Value

P-Value

n sites

Combined MOUD

6.456

3.175

.002

35

1.836

0.698

.485

30

Buprenorphine

4.560

3.374

<.001

29

7.704

3.380

<.001

25

Methadone

2.484

1.599

.111

34

-4.524

-2.453

.015

29

Naltrexone

0.204

1.190

.235

32

-0.240

-1.174

.241

27

Baseline Intercept

13.604

25.160

Census Counts of MOUD

Sustainability Phase (12 Ms)

Annual Est. Change

T-Value

P-Value

n sites

Annual Est. Change

T-Value

P-Value

n sites

Combined MOUD

22.944

4.365

< .001

36

7.404

2.012

.045

31

Buprenorphine

10.260

4.150

< .001

30

13.236

4.812

< .001

27

Methadone

3.864

1.565

0.118

35

-04.644

-1.780

.076

31

Naltrexone

0.876

2.348

0.020

32

1.032

2.367

0.019

26

Baseline Intercept

47.423

72.431